
According to data from Benzinga Pro, during Q1, Reata Pharmaceuticals's (NASDAQ:RETA) reported sales totaled $914.00 thousand. Despite a 13.52% increase in earnings, the company posted a loss of $73.84 million. In Q4, Reata Pharmaceuticals brought in $934.00 thousand in sales but lost $85.39 million in earnings.